Clinical Trial Update: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study evaluates CKD-501 in patients with hepatic impairment to understand how liver dysfunction affects drug exposure and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• CKD-501

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Liver Dysfunction | Phase 1 | Status: COMPLETED